Sorafenib may provide clinical benefit for patients with locally advanced or metastatic chordomas, a new study published online ahead of print in the journal Annals of Oncology has shown.
Because there is consensual treatment for patients with locally advanced or metastatic chordomas, a rare type of sarcoma that occurs in the skull base and along the spine, researchers sought to evaluate the safety and efficacy of sorafenib as a potential treatment.
For the multicenter, open-label, uncontrolled phase 2 trial, researchers enrolled 27 patients with locally advanced or metastatic chordomas between May 2011 and January 2014. Of those, 12 had previously received chemotherapy and molecularly targeted agents to treat their disease.
Results showed an intent-to-treat best objective response rate of 3.7% (95% CI: 0.1, 19.0), a 9-month progression-free rate of 73.0% (95% CI: 46.1, 88.0), and a 12-month overall survival rate of 86.5% (95% CI: 55.8, 96.5).
RELATED: Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Analyses demonstrated similar survival curves among pre-treated patients and non-pre-treated patients.
In regard to safety, 77.8% and 14.8% of patients experienced grade 3 and 4 toxicities, respectively.
The findings suggest that further studies are warranted to assess the value of sorafenib as a treatment for patients with locally advanced or metastatic chordomas.